Trosyd AF
Trosyd AF Brand names, Trosyd AF Analogs
- Fungibacid
- GyneCure
- GyneCure Ovules
- GyneCure Vaginal Ointment Tandempak
- GyneCure Vaginal Ovules Tandempak
- Gyno-trosyd
- Monistat 1
- Oxiconazolc Nitrate
- Oxiconazole
- Oxiconazole nitrate
- Thioconazole
- Tioconazol [INN-Spanish]
- Tioconazole [USAN:BAN:INN:JAN]
- Tioconazolum [INN-Latin]
- Trosyd
- Trosyd AF
- Trosyd J
- Trosyl
- Tz-3
- Vagistat
- Vagistat-1
- Zoniden
Trosyd AF Brand Names Mixture
- No information avaliable
Trosyd AF Chemical_Formula
C8H15NO2
Trosyd AF RX_link
http://www.rxlist.com/cgi/generic3/cyclapron.htm
Trosyd AF fda sheet
Trosyd AF msds (material safety sheet)
Trosyd AF Synthesis Reference
No information avaliable
Trosyd AF Molecular Weight
157.21 g/mol
Trosyd AF Melting Point
>300 oC
Trosyd AF H2O Solubility
1.67E+005 mg/L
Trosyd AF State
Solid
Trosyd AF LogP
0.66
Trosyd AF Dosage Forms
Tablets containing 500 mg of tranexamic acid; Sterile solution for intravenous injection containing 100 mg tranexamic acid
Trosyd AF Indication
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Trosyd AF Pharmacology
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Trosyd AF Absorption
Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
Trosyd AF side effects and Toxicity
Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
Trosyd AF Patient Information
Trosyd AF Organisms Affected
Humans and other mammals
